Search results for query: *

  • Users: lynnbr2
  • Content: Threads
  • Order by date
  1. L

    Stem cells show promise in Phase I/IIa trial - CNS10-NPC-GDNF

    “Because [these stem cells] are engineered to release GDNF, we get a ‘double whammy’ approach where both the new cells and the [GDNF] protein could help dying motor neurons survive better in this disease,”...
  2. L

    Apolipoprotein B-100, a possible CSF chelation treatment Target?

    This still has a long way to go, but, "Our data clearly show that ApoB is sufficient to induce motor disability and motor neuron degeneration, and its removal from sALS CSF via filtration or immunodepletion attenuates neurotoxicity, establishing a novel sALS-specific therapeutic target and...
  3. L

    CMS Opens Consideration for Seat Elevation Systems Coverage, A public comment period on seat elevation systems coverage is open until September 14.

    PLEASE WEIGH IN!! This would free up Team Gleason to fund other things...
  4. L

    Astrocyte study explains why Riluzole helps

    recent studies show that Riluzole can provide up to 12-16 months benefit. This first study talks about Glutamate. https://academic.oup.com/brain/article/145/2/481/6510848 https://genome.cshlp.org/content/early/2021/12/28/gr.275939.121
  5. L

    Amylyx has not yet disclosed its price for: The drug, known as Albrioza or AMX0035, not a good sign.

    The entire Pharma Industry is watching. https://www.biopharmadive.com/news/amylyx-icer-als-drug-price-cost-effective/625443/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202022-06-14%20BioPharma%20Dive%20%5Bissue:42419%5D&utm_term=BioPharma%20Dive
  6. L

    Another occupational exposure study

    https://link.springer.com/article/10.1007/s00420-022-01874-4
Back
Top